peptide wiki

PT-141

Melanocortin research-only

Mechanism

No mechanism summary on file.

Identification

CAS number189691-06-3
Molecular formulaC50H68N14O10

Safety

Active ingredient (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women (AMAG Pharmaceuticals, 2019). Research-market PT-141 is not Vyleesi and is not FDA-controlled. Documented side effects include flushing, transient hypertension, nausea, and dose-dependent hyperpigmentation.

Vendors selling PT-141

VendorSizePriceListed purityTrust
Nuscience Peptides 60
Peptide Sciences 26

Research

Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.
Ila V, Pozzi E, Gamage M, et al. · Expert Opin Pharmacother (2025) · review
source →
Melanocortins in the treatment of male and female sexual dysfunction.
Shadiack AM, Sharma SD, Earle DC, et al. · Curr Top Med Chem (2007) · review
source →
Bremelanotide.
· (2006) · review
source →
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.
Hadley ME, Dorr RT · Peptides (2006) · review
source →
Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol (2005) ·
source →
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Diamond LE, Earle DC, Garcia WD, et al. · Urology (2005) · rct
source →
Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol (2004) ·
source →
PT-141 Palatin.
Hedlund P · Curr Opin Investig Drugs (2004) · review
source →
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
Rosen RC, Diamond LE, Earle DC, et al. · Int J Impot Res (2004) · rct
source →
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
Molinoff PB, Shadiack AM, Earle D, et al. · Ann N Y Acad Sci (2003) · rct
source →